EXO‑CD24
Acute Respiratory Distress Syndrome (ARDS)
Phase 2Active
Key Facts
About Nano24med
Exosome‑delivered CD24 immunomodulator for ARDS and cytokine‑storm diseases.
View full company profileAbout Nano24med
Exosome‑delivered CD24 immunomodulator for ARDS and cytokine‑storm diseases.
View full company profileTherapeutic Areas
Other Acute Respiratory Distress Syndrome (ARDS) Drugs
| Drug | Company | Phase |
|---|---|---|
| MultiStem | Athersys | Phase 3 |
| BXT-25 | BioXyTran | Preclinical |
| Bioengineered Surfactant Program | BioSuperior | Pre-clinical |
| FX06 | F4 Pharma | Phase 1/2 |
| AVM0703 | AVM Biotechnology | Pre-clinical / Research |
| ACE2v2-Fc | Cyrus Biotechnology | Preclinical |
| GEn-1124 | GEn1E Lifesciences | Phase 2 |
| AZM-152 | Azome Therapeutics | Pre-clinical |
| Zelpultide Alfa | Airway Therapeutics | Pre-clinical/Research |
| ALT-100 mAb | Aqualung Therapeutics | Phase 2a |
| RP-323 | PhorMed | Phase 2 |
| Research Grant: Effect of volatile sedation on spontaneous breathing in ARDS | Sedana Medical | Investigator-Initiated Trial |